RAPS eCTD training workshop

Published: 18-Oct-2017

The FDA’s May 2018 deadline mandates that you comply with new requirements surrounding the submission of applications using eCTD. If you are currently preparing and maintaining paper ASMFs and DMFs and/or Module 3 in eCTD for the EU, US, Canada, and/or Switzerland and have to use the eCTD format, this course will help you to prepare compliant electronic submissions to FDA.

As an attendee, you will learn how to successfully meet these regulatory requirements and gain a deep understanding of the processes needed to build electronic submissions and implement operational changes that will lead to successful electronic regulatory applications.

The course will also provide an overview of the difference between submissions to US, EU, Canada, and Switzerland and help you understand how to prepare for each.

Join RAPS for this intense two-day, hands-on compilation training that will answer your submission questions and help you get on a direct path to compliance.

Note: each participant must bring his/her own laptop for use during the class. RAPS does not supply computer equipment for attendees

Event venue: Frankfurt Holiday Inn—Alte Oper, Mainzer Landstraße 27, DE-60329

Organiser: Regulatory Affairs Professionals Society (RAPS)

Registration fees: RAPS members $1,450, non-members $1,550. Use code REC17 for $100 off.

Web: raps.org or click here to register for this course

Trending Articles

  1. Cleanroom Conference UK 22–23 May 2024 | Exhibition | Birmingham, UK
  2. Lounges 23-25 April 2024 | Conference | Messe Karlsruhe, Germany
  3. Making Pharmaceuticals 23–24 April 2024 | Exhibition | Coventry, UK
  4. Interphex 16-18 April 2024 | Conference and Exhibition | New York, US
  5. CPhI North America 7-9 May 2024 | Exhibition | Pennsylvania, US

You may also like

Regulatory

Euro Convergence 2020 Live Online new dates

26–30 October 2020 | Virtual event
Regulatory

USP and British counterpart join forces

Pharmacopoeias in the US and in the UK have signed a memorandum of understanding to strengthen quality standards for medicines
Regulatory

RAPS Europe Conference 2019 to address sweeping changes in European regulatory environment

The event in May comes as a host of new laws affecting the medicines, medical devices and <em>in vitro</em> diagnostics (IVDs) sectors are due to come into effect
Regulatory

Waiting in the shadow of a no deal Brexit

Pharmaceutical companies still do not know how they will be impacted by Brexit after Prime Minister Theresa May decided to postpone a vote on her deal with the European Union (EU), writes Paul Brooks, Executive Director, RAPS
Regulatory

RAPS publishes compensation survey of regulatory professionals

Offering a look at how much healthcare product regulatory professionals earn, which products they work on, what their work entails and how their roles have evolved
Regulatory

MPs back amendment to keep UK in EU medicines regulatory network

Industry insiders comment on disruptions to the supply of medicines post-Brexit and what the MPs backed amendment means for British patients
Regulatory

Brexit trade bill: Not yet

The UK has decided it will continue to be involved with the European Medicines Agency (EMA) after Brexit. Paul Brooks, Executive Director at the Regulatory Affairs Professionals Society (RAPS) asks what does this mean for the pharmaceutical industry and patients after 2020?
Subscribe now